Share

February 13, 2018; 90 (7) Article

Smoking affects the interferon beta treatment response in multiple sclerosis

Eva R. Petersen, Annette B. Oturai, Nils Koch-Henriksen, Melinda Magyari, Per S. Sørensen, Finn Sellebjerg, Helle B. Søndergaard
First published January 17, 2018, DOI: https://doi.org/10.1212/WNL.0000000000004949
Full PDF
Citation
Permissions

Comment

Downloads
133

Share

Article Information

vol. 90 no. 7 e593-e600
DOI: 
https://doi.org/10.1212/WNL.0000000000004949
PubMed: 
29343473
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received February 3, 2017
  • Accepted in final form November 2, 2017
  • First Published January 17, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Information

    1. Eva R. Petersen, MD,
    2. Annette B. Oturai, MD, PhD,
    3. Nils Koch-Henriksen, MD, DMSc,
    4. Melinda Magyari, MD, PhD,
    5. Per S. Sørensen, MD, DMSc,
    6. Finn Sellebjerg, MD, PhD, DMSc and
    7. Helle B. Søndergaard, MSc, PhD
  1. Eva R. Petersen, MD,
    2. Scientific Advisory Boards:

    1. I have served on scientific advisory board for Teva (Denmark)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. As mentioned in the manuscript the study was supported by The Danish Multiple Sclerosis Society, the Danish Council for Strategic Research, NOVARTIS, BIOGEN IDEC and The Foundation for Research in Neurology.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Annette B. Oturai, MD, PhD,
    3. Scientific Advisory Boards:

    1. (1) Dr. Annette Bang Oturai has served on scientific advisory boards for Sanofi Genzyme and Biogen Idec.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Has received speaker honoraria from Biogen Idec, Novartis and TEVA; and has received support for congress participation from, Merck Serono, TEVA, Biogen, Novartis and Sanofi Genzyme.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. My laboratory has received research support from Biogen Idec and Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. This study was supported by The Danish Multiple Sclerosis Society, the Danish Council for Strategic Research, NOVARTIS, BIOGEN IDEC and The Foundation for Research in Neurology.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Nils Koch-Henriksen, MD, DMSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Nils Koch-Henriksen has received travel expenses for attending congresses and meetings from BiogenIdec, Mercx, and TEVA.

    Editorial Boards:

    1. Multiple Sclerosis and Related Disorders (since establishment)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Melinda Magyari, MD, PhD,
    5. Scientific Advisory Boards:

    1. (1)Biogen (2)Teva (3) Sanofi (3)Roche (4) Merck (5) Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Biogen (2)Teva (3) Sanofi (4)Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Roche (2) KORA: Det Nationale Institut for Kommuners og Regioners Analyse og Forskning

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Biogen (2)Teva (3) Sanofi (3)Roche (4) Merck (5) Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Per S. Sørensen, MD, DMSc,
    6. Scientific Advisory Boards:

    1. Scientific advisory boards for Biogen Idec, Merck, Novartis, Teva Pharmaceutical Industries Ltd., Forward Pharma, MedDay pharmaceuticals, Genzyme, Celgene; Steering committees or independent data monitoring boards in clinical trials sponsored by Merck, Teva Pharmaceutical Industries Ltd., Novartis, and GlaxoSmithKline

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaker honoraria from Biogen Idec, Merck, Teva Pharmaceutical Industries Ltd., sanofi-aventis, Genzyme, and Novartis

    Editorial Boards:

    1. Previous Editor-in-Chief European Journal of Neurology, Editorial Board: European Journal of Neurology, Therapeutic Advances in Neurological Disorders, Multiple Sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Honoraria for lecturing from Biogen Idec, Merck, TEVA, and Novartis

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. The department of Neurology, Rigshospitalet have received unrestricted research grant or compensation for participation in pharmaceutical company sponsored clinical trials from Biogen Idec, Merck, TEVA, Sanofi-aventis/Genzyme, Novartis, RoFAR, and Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Danish Multiple Sclerosis Society, Danish Medical Research Council, and European Union

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Finn Sellebjerg, MD, PhD, DMSc and
    7. Scientific Advisory Boards:

    1. (1) Biogen-Idec (2) Genzyme (3) Merck Serono (4) Sanofi- Aventis (5) Teva (6) Novo Nordisk

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer Schering, speaker honoraria, (2) Biogen Idec, funding for travel and speaker honoraria, (3) Genzyme, speaker honoraria, (4) Merck Serono, speaker honoraria, (5) Novartis, funding for travel and speaker honoraria, (6) Sanofi-Aventis, funding for travel and speaker honoraria (6) Schering-Plough, speaker honoraria (7) Teva, funding for travel 2008 (Teva and Sanofi-Aventis).

    Editorial Boards:

    1. Multiple Sclerosis and Related Disorders. Section editor (immunology).

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biogen Idec

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Idec, Sanofi-Aventis, Novartis

    Research Support, Government Entities:

    1. Danish Strategic Research Council (2009- 2013), grant number 2142-08-0039.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Danish Multiple Sclerosis Society (2) Lounk?r Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Helle B. Søndergaard, MSc, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Helle Bach S?ndergaard has received support for congress participation from Biogen Idec, Genzyme and Teva.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Sclerose Foreningen, MS networks and immunogenetics, 2015 A.P.M?ller Fonden-Fonden til l?gevidenskabens fremme, MS networks and immunogenetics, 2015

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark.
  1. Correspondence
    Dr. Petersen Evarosapetersen{at}gmail.com
View Full Text

Article usage

Article usage: January 2018 to July 2018

AbstractFullPdfSource
Jan 2018418044Highwire
Feb 201810467944Highwire
Mar 20183041818Highwire
Apr 20182671214Highwire
May 201820525Highwire
Jun 201816557Highwire
Jul 201814511Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me